Why Rashida Najmi believes in running quality on trust, not vigilance
In your article for Express Pharma in April 2019, you mentioned that quality needs to be part of culture, beyond compliance.…
Author
How Pivot Path is in a sweet spot to address pharma’s pressure points
Pivot Path emerged from Strides Pharma's internal GCC. Are other pharma companies also following the same playbook? And if so,…
Why India’s medicines need integrated authentication, enforceable standards
Triggered by recent high profile operations involving counterfeit semaglutide in the domestic markets and anti-rabies vaccines…
Diversifying beyond the US market
India's next export wave will not be won on tariff advantage alone; mutual recognition of standards and regulatory cooperation…
Why India’s biopharma value shift could unlock an additional $125-bn opportunity
What are the broad global consumer health trends driving the global biopharma sector this decade?
We believe that global…
Why weight loss cannot be an aesthetic goal
How has the launch of GLP-1 medication disrupted weight loss/obesity care models globally?
For a long time, obesity care was…
India is one of Zoetis’ strongest markets in Asia for in-ovo vaccination
The recent H5N1 avian influenza resurgence in poultry farms in certain districts of Maharashtra and Karnataka once again reminds…
The fine line between reform and risk
A couple of recent notifications, one a notified amendment and the second one, a proposed amendment, concerning medicines have…
Financial strategies for uncertain times
Inspite of current geopolitical disruptions,both larger pharma enterprises and smaller promoter-driven entities are playing for…
India is well on its path to strongly push back the perception battle of quality
As we mark International Clinical Trial Day today, Dr Seema Pai, President, ISCR explains to Viveka Roychowdhury why it is…